莫沙必利联合雷贝拉唑治疗胃食管反流引起慢性喉炎的效果及对血清胃泌素的影响  

Effect of mosapride combined with rabeprazole in the treatment of chronic laryngitis caused by gastroesophageal reflux and its effect on serum gastrin

作　　者：卢美美 武新荣 赵勇 LU Meimei;WU Xinrong;ZHAO Yong(Jiaozuo Coal Industry(Group)Co.,Ltd.,Central Hospital Otolaryngology Department,Jiaozuo 454000,Henan,China)

机构地区：[1]焦作煤业(集团)有限责任公司中央医院耳鼻咽喉科,河南焦作454000

出　　处：《中国校医》2024年第10期772-776,共5页Chinese Journal of School Doctor

摘　　要：目的探讨莫沙必利联合雷贝拉唑治疗胃食管反流引起慢性喉炎的疗效及对血清胃泌素、炎症因子水平的影响。方法回顾性分析2021年4月—2022年4月焦作煤业(集团)有限责任公司中央医院收治的93例胃食管反流引起慢性喉炎患者的临床资料,按治疗方法不同分为雷贝拉唑组(31例)、莫沙必利组(31例)、莫沙必利联合雷贝拉唑组(31例),3组均持续治疗8周。对比3组临床疗效、血清胃泌素及食管下括约肌压力、反流症状指数量表(RSI)评分及反流体征量表(RFS)评分、生活质量及不良反应。结果雷贝拉唑组治疗总有效率为70.97%(22/31),莫沙必利组治疗总有效率为74.19%(23/31),莫沙必利联合雷贝拉唑组治疗总有效率为96.77%(30/31),差异有统计学意义(P<0.05)。治疗前,3组血清胃泌素及食管下括约肌压力比较,差异无统计学意义(P>0.05);治疗后,雷贝拉唑组血清胃泌素为(12.26±1.77)pg/mL,食管下括约肌压力(30.66±2.89)mmHg,莫沙必利组血清胃泌素为(12.35±1.86)pg/mL,食管下括约肌压力(31.46±2.98)mmHg,莫沙必利联合雷贝拉唑组血清胃泌素为(16.35±1.97)pg/mL,食管下括约肌压力(36.29±3.18)mmHg,差异均有统计学意义(P均<0.05)。治疗前,3组RSI评分及RFS评分比较,差异无统计学意义(P>0.05);治疗后,雷贝拉唑组RSI评分为(12.32±2.98)分,RFS评分为(8.21±1.24)分,莫沙必利组RSI评分为(12.41±2.88)分,RFS评分为(8.36±1.32)分,莫沙必利联合雷贝拉唑组RSI评分为(9.12±2.02)分,RFS评分为(6.17±1.08)分,差异均有统计学意义(P均<0.05)。治疗前,3组生活质量比较,差异无统计学意义(P>0.05);治疗后,雷贝拉唑组社会功能为(71.22±5.89)分,心理功能为(73.33±5.97)分,躯体功能为(74.81±5.95)分,物质生活状态为(70.98±5.42)分,莫沙必利组社会功能为(72.79±4.15)分,心理功能为(74.57±3.22)分,躯体功能为(75.44±4.13)分,物质生活状态为(70.51±4.03)分,莫沙必利联合雷贝拉唑组社Objective This study was aimed at exploring the efficacy of moxapride combined with rabeprazole in the treatment of chronic laryngitis caused by gastroesophageal reflux,including the effects on serum gastrin and inflammatory factors.Methods Clinical data for 93 patients with chronic laryngitis caused by gastroesophageal reflux,who were admitted to Central Hospital of Jiaozao Coal Industry(Group)Co.,Ltd.,between April 2021 and April 2022 were retrospectively analyzed.According to treatment method,the patients were divided into a rabeprazole group(31 cases),moxapride group(31 cases),or moxapride plus rabeprazole group(31 cases).All three groups were treated for 8 weeks.The clinical efficacy,serum gastrin,lower esophageal sphincter pressure,Reflux Symptom Index(RSI)score,Reflux Signs Scale(RFS)score,quality of life,and adverse reactions were compared among groups.Results The total effective rate was 70.97%(22/31)in the rabeprazole group,74.19%(23/31)in the moxapride group,and 96.77%(30/31)in the moxapride plus rabeprazole group;the differences were statistically significant(P<0.05).Before treatment,no significant differences in serum gastrin and lower esophageal sphincter pressure were observed among groups(P>0.05).After treatment,the serum gastrin and lower esophageal sphincter pressure were 12.26±1.77 pg/ml and 30.66±2.89 mmHg,respectively,in the rabeprazole group,and 12.35±1.86 pg/ml and 31.46±2.98 mmHg,respectively,in the moxaprilide group.The serum gastrin and lower esophageal sphincter pressure were 16.35±1.97 pg/ml and 36.29±3.18 mmHg,respectively,in the mosaporide plus rabeprazole group,and the differences were statistically significant(both P<0.05).Before treatment,we observed no significant differences in the RSI score and RFS score among groups(P>0.05).After treatment,the RSI score and RFS score were 12.32±2.98 and 8.21±1.24,respectively,in the rabeprazole group,and 12.41±2.88 and 8.36±1.32,respectively,in the moxapride group.The RSI score and RFS score in the moxapride plus rabeprazole group we

关 键 词：胃食管反流 慢性喉炎 莫沙必利 雷贝拉唑 血清胃泌素 不良反应 

分 类 号：R571[医药卫生—消化系统] R767.11[医药卫生—内科学]